Impact of intraduodenal acetic acid infusion on pancreatic duct cannulation during endoscopic retrograde cholangiopancreatography: A double‐blind, randomized controlled trial

Fang, Jun; Wang, Shuling; Zhao, Shengbing; Hu, Liang‐Hao; Yao, Jun; Shen, Zhen; Gu, Lun; Xia, Tian; Cai, Qiang; Li, Zhao‐Shen; Bai, Yu

doi:10.1111/jgh.14148

Cited by 7 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The limitations of secretin, such as its high price and limited availability, makes its use complicated in clinics[97]. Alternatively, intraduodenal acid infusion (ACI) was used in clinical trials, since it can physiologically stimulate secretin release in the body[98,99].…”

Section: Resultsmentioning

confidence: 99%

“…Alternatively, intraduodenal acid infusion (ACI) was used in clinical trials, since it can physiologically stimulate secretin release in the body[98,99]. Fang et al[97] conducted a single center, double-blind RCT between 2016 and 2017 in China to investigate the impact of ACI on pancreatic duct cannulation during ERCP. Consecutive patients were randomized into two groups (105 in each group) and received 50 mL ACI infusion or 50 mL saline.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment

Pekgöz

2019

WJG

View full text Add to dashboard Cite

BACKGROUND Post endoscopic retrograde cholangiopancreatography (ERCP) is comparatively complex application. Researchers has been investigated prevention of post-ERCP pancreatitis (PEP), since it has been considered to be the most common complication of ERCP. Although ERCP can lead various complications, it can also be avoided. AIMS To study the published evidence and systematically review the literature on the prevention and treatment for PEP. METHODS A systematic literature review on the prevention of PEP was conducted using the electronic databases of ISI Web of Science, PubMed and Cochrane Library for relevant articles. The electronic search for the review was performed by using the search terms “Post endoscopic retrograde cholangiopancreatography pancreatitis” AND “prevention” through different criteria. The search was restricted to randomized controlled trials (RCTs) performed between January 2009 and February 2019. Duplicate studies were detected by using EndNote and deleted by the author. PRISMA checklist and flow diagram were adopted for evaluation and reporting. The reference lists of the selected papers were also scanned to find other relevant studies. RESULTS 726 studies meeting the search criteria and 4 relevant articles found in the edited books about ERCP were identified. Duplicates and irrelevant studies were excluded by screening titles and abstracts and assessing full texts. 54 studies were evaluated for full text review. Prevention methods were categorized into three groups as (1) assessment of patient related factors; (2) pharmacoprevention; and (3) procedural techniques for prevention. Most of studies in the literature showed that young age, female gender, absence of chronic pancreatitis, suspected Sphincter of Oddi dysfunction, recurrent pancreatitis and history of previous PEP played a crucial role in posing high risks for PEP. 37 studies designed to assess the impact of 24 different pharmacologic agents to reduce the development of PEP delivered through various administration methods were reviewed. Nonsteroidal anti-inflammatory drugs are widely used to reduce risks for PEP. Rectal administration of indomethacin immediately prior to or after ERCP in all patients is recommended by European Society for Gastrointestinal Endoscopy guidelines to prevent the development of PEP. The majority of the studies reviewed revealed that rectally administered indomethacin had efficacy to prevent PEP. Results of the other studies on the other pharmacological interventions had both controversial and promising results. Thirteen studies conducted to evaluate the efficacy of 4 distinct procedural techniques to prevent the development of PEP were reviewed. Pancreatic Stent Placement has been frequently used in this sense and has potent and promising benefits in the prevention of PEP. Studies on the other procedural techniques have had inconsistent results. CONCLUSION Prevention of PE...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment

Pekgöz

2019

WJG

View full text Add to dashboard Cite

show abstract

“…However, whether SCT is an oncogene or a tumor suppressor is still controversial. A number of studies hold the idea that it is an oncogene, as high expression was observed in breast cancer [44], whereas other studies indicated the downregulation of the gene in colorectal cancer [45] and prostate cancer [46]. SCT acts as a gene with double-edge sword activities, which possesses both oncogenic and tumorsuppressive effects.…”

Section: Discussionmentioning

confidence: 99%

Berberine Inhibits the Expression of SCT through miR‐214‐3p Stimulation in Breast Cancer Cells

Zhu

Hua

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

In this study, we aimed to evaluate the suppressive abilities of berberine (BBR) on MCF-7 and MDA-MB-231 cells and confirm its underlying mechanisms on miR-214-3p. We first built a panel of 18 miRNAs and 9 lncRNAs that were reported to participate in the mechanism of breast cancer. The RT-qPCR results suggested that BBR illustrated a dosage-dependent pattern in the stimulation to miR-214-3p in both MCF-7 and MDA-MB-231 cells. Then, we performed gain-and-lose function tests to validate the role of miR-214-3p contributing to the anticancer effects of BBR. Both BBR and miR-214-3p mimic reduced the cell viability, repressed migration and invasion capacities, increased rates of total apoptotic cells and ratio of Bax/Bcl-2, and increased the percentage of G2/M cells of MCF-7 and MDA-MB-231 cells by colony formation and CKK8 assay, scratch wound healing and gelatin-based 3D conformation assay, transwell invasion assay, and cell cycle analysis, respectively. However, miR-214-3p inhibitor counteracted all these effects of BBR. Based on the bioinformatics analysis and dual-luciferase reporter test, we identified binding sites between SCT and miR-214-3p. We further confirmed that BBR massively and dose-dependently reduced the mRNA expression and protein levels of SCT in both MCF-7 and MDA-231 cells. We testified that both miR-214-3p mimic and BBR could decrease the mRNA expression and protein levels of SCT, while miR-214-3p inhibitor weakened these reductions. In conclusion, BBR suppressed MCF-7 and MDA-MB-231 breast cancer cells by upregulating miR-214-3p and increasing its inhibition to SCT.

show abstract

“…Assim, a admistração do análogo de secretina, que é um hormônio peptídico gastrointestinal o qual promove a liberação pancreática de bicarbonato, pode contribuir para a canulação. As limitações desse hormônio tornam o seu uso inviável pelos hospitais, visto que possui alto preço, bem como pouca disponibilidade (FUNG et al, 2021) A infusão intraductal de ácido acético, também, pode facilitar a canulação. É uma abordagem fisiológica que estimula a liberação de secretina endógena.…”

Section: Farmacoprevençãounclassified

“…É uma abordagem fisiológica que estimula a liberação de secretina endógena. Em um ensaio clínico randomizado e duplo-cego com 210 pacientes observou que esse ácido pode diminuir a taxa de canulação do ducto biliar comum (FANG et al, 2018) Alguns outros medicamentos foram estudados para tentar reduzir o bloqueio temporal do fluxo de eliminação do suco pancreático, causado pelo edema papilar e/ou espasmo do esfíncter de Oddi. Dentre eles, o gliceriltrinitrato e o nitrato de glicerila que auxiliam no relaxamento do esfíncter de Oddi e facilita a canulação primária.…”

Section: Farmacoprevençãounclassified

Pancreatite pós-colangiopancreatografia retrógrada endoscópica: uma revisão narrativa

Filho¹,

Silva²

2022

BJDV

View full text Add to dashboard Cite

A pancreatite é a complicação mais frequente e, potencialmente, mais agressiva da colangiopancreatografia retrógrada endoscópica (CPRE), resultando em alta morbidade, mortalidade episódica e aumento dos dispêndios com saúde. Nesse sentido, a prevenção da pancreatite pós-CPRE (PPC) segue como um desafio, tornando-se prioridade no meio científico, assim como no meio clínico. O presente artigo contou com o objetivo principal apresentar os estudos publicados sobre pancreatite pós-colangiopancreatografia retrógrada endoscópica, com ênfase nos fatores de risco e preventivos, através de uma revisão narrativa nos bancos de dados PubMed, CAPES, SciELO, BVS e Cochrane Library nos idiomas inglês, espanhol e português com recorte temporal dos últimos 5 anos. Para minimizar a taxa de incidência, perpassa por selecionar o paciente com critérios, estratificar os riscos, além de usar os fármacos para a prevenção, selecionar a melhor técnica e colocar o stent pancreático profilaticamente. Embora nos últimos anos tenha tido progressos nesses setores de pesquisa, ainda persiste uma alta taxa de incidência, podendo variar até 15%. Dessa forma, novas áreas devem ser exploradas com o intuito de mitigar a PPC.

show abstract

Impact of intraduodenal acetic acid infusion on pancreatic duct cannulation during endoscopic retrograde cholangiopancreatography: A double‐blind, randomized controlled trial

Abstract: Intraduodenal acetic acid infusion can significantly decrease difficult pancreatic cannulation rate, facilitate pancreatic duct cannulation, and reduce radiation exposure (ClinicalTrials.gov number, NCT02800772).

Cited by 7 publications

References 29 publications

Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment

Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment

Berberine Inhibits the Expression of SCT through miR‐214‐3p Stimulation in Breast Cancer Cells

Pancreatite pós-colangiopancreatografia retrógrada endoscópica: uma revisão narrativa

Contact Info

Product

Resources

About